NASDAQ:IMDZ - Immune Design Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$5.85
+0.30 (1.20%)
Get New Immune Design Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMDZ and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMDZ

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Immune Design in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $5.85.

This chart shows the closing price for IMDZ for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Immune Design. This rating has held steady since January 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/31/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/22/2019Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$9.00 ➝ $6.00Low
2/21/2019HC WainwrightDowngradeBuy ➝ NeutralN/A
1/14/2019HC WainwrightReiterated RatingBuy$8.00Medium
12/3/2018HC WainwrightReiterated RatingBuy$8.00Low
11/7/2018HC WainwrightSet Price TargetBuy$8.00Low
10/12/2018HC WainwrightSet Price TargetBuy$11.00 ➝ $8.00High
10/12/2018Royal Bank of CanadaReiterated RatingOutperform$11.00High
10/12/2018SVB LeerinkDowngradeOutperform ➝ Market PerformHigh
8/29/2018HC WainwrightInitiated CoverageBuy$11.00High
3/15/2018Jefferies Financial GroupReiterated RatingBuy$8.00High
12/11/2017CowenReiterated RatingBuyLow
10/17/2017Wells Fargo & CompanyDowngradeOutperform ➝ Market Perform$29.00 ➝ $10.00N/A
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$20.00Low
6/28/2017Jefferies Financial GroupReiterated RatingBuy$18.00Medium
6/6/2017CowenReiterated RatingBuyHigh
5/19/2017Jefferies Financial GroupReiterated RatingBuy$16.00 ➝ $18.00Medium
3/8/2017Jefferies Financial GroupBoost Price TargetBuy$15.00 ➝ $16.00High
2/21/2017Jefferies Financial GroupReiterated RatingBuy$15.00N/A
11/13/2016CowenReiterated RatingBuyN/A
11/10/2016Jefferies Financial GroupLower Price TargetBuy$17.00 ➝ $15.00N/A
10/25/2016Jefferies Financial GroupReiterated RatingBuy$17.00N/A
8/10/2016Jefferies Financial GroupReiterated RatingBuy$20.00 ➝ $17.00N/A
(Data available from 6/24/2016 forward)
Immune Design logo
Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma. The company is also developing CA21, a multi-targeting prime boost for the treatment of multiple solid tumors; and ZVex-IL12 for the treatment of TBD tumors. In addition, its technologies are used in the fields of infectious and allergic diseases. The company has license agreements with California Institute of Technology, University of North Carolina at Chapel Hill, TheraVectys SA, Infectious Disease Research Institute, MedImmune LLC, and Sanofi; and a collaboration agreement with Sanofi Pasteur. Immune Design Corp. was founded in 2008 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $5.85
Low: $5.85
High: $5.85

50 Day Range

MA: $5.85
Low: $5.85
High: $5.85

52 Week Range

Now: $5.85
Low: $1.10
High: $5.85

Volume

N/A

Average Volume

374,216 shs

Market Capitalization

$282.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.48

Frequently Asked Questions

What sell-side analysts currently cover shares of Immune Design?

The following sell-side analysts have issued stock ratings on Immune Design in the last twelve months:
View the latest analyst ratings for IMDZ.

What is the current price target for Immune Design?

0 Wall Street analysts have set twelve-month price targets for Immune Design in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Immune Design in the next year.
View the latest price targets for IMDZ.

What is the current consensus analyst rating for Immune Design?

Immune Design currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for IMDZ.

What other companies compete with Immune Design?

How do I contact Immune Design's investor relations team?

Immune Design's physical mailing address is 1616 EASTLAKE AVENUE EAST SUITE 310, SEATTLE WA, 98102. The biotechnology company's listed phone number is 206-682-0645 and its investor relations email address is [email protected] The official website for Immune Design is www.immunedesign.com.